-
Track & Monitor
Innovation in automotive: Multi-link electric powertrains
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s Multi-link electric powertrains segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in automotive: Integrated multi-motor drivetrains
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the automotive industry’s Integrated multi-motor drivetrains segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Verdiperstat in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Verdiperstat in Multiple System...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ION-464 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ION-464 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ION-464 in Multiple System...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LuAF-82422 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LuAF-82422 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LuAF-82422 in Multiple System...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) Vaccine in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) Vaccine in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Multi-epitope (ME) T-cell...
-
Product Insights
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2023
Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2023’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emrusolmin in Multiple System...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ONO-2808 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ONO-2808 in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ONO-2808 in Multiple System...
-
Product Insights
Multi Tambangjaya Utama Mine
The Multi Tambangjaya Utama Mine is a coal mine in Indonesia. It is currently in operation. Empower your strategies with our Multi Tambangjaya Utama Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to...